# Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

> **NCT05836571** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute LAO** · enrollment: 66 (estimated)

## Conditions studied

- Locally Advanced Extraskeletal Myxoid Chondrosarcoma
- Locally Advanced Leiomyosarcoma
- Locally Advanced Liposarcoma
- Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Locally Advanced Unresectable Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Unresectable Leiomyosarcoma
- Unresectable Liposarcoma
- Unresectable Undifferentiated Pleomorphic Sarcoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05836571
- **Lead sponsor:** National Cancer Institute LAO
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836571, "Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05836571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*